{
    "nctId": "NCT00436566",
    "briefTitle": "Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery",
    "officialTitle": "Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Plus Trastuzumab With Lapatinib in Patients With Resected HER2 + Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Cardiac Toxicity",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 122,
    "primaryOutcomeMeasure": "Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed diagnosis of early-stage breast cancer\n\n  * HER2 positive by immunohistochemistry (IHC) (3+) or fluorescent in situ hybridization (FISH)\n\n    * Ductal carcinoma in situ (DCIS) components should not be counted in the determination of degree of IHC staining or FISH amplification\n* No locally advanced tumors (i.e., T4) at diagnosis, including the following:\n\n  * Tumors fixed to chest wall\n  * Peau d'orange\n  * Skin ulcerations or nodules\n  * Clinical inflammatory changes (e.g., diffuse brawny cutaneous induration with an erysipeloid edge)\n* Has undergone mastectomy or lumpectomy with axillary node or sentinel node dissection within the past 84 days\n\n  * Patients who have undergone a mastectomy must meet the following criteria:\n\n    * No evidence of gross or microscopic tumor (i.e., invasive DCIS) at the surgical resection margins noted in final surgery or pathology reports\n\n      * Patients with close margins are eligible\n    * Radiation therapy is required for 4 or more positive lymph nodes and must be started after completion of chemotherapy\n  * Patients who have undergone a lumpectomy with axillary node or sentinel node dissection must meet the following criteria:\n\n    * No evidence of invasive cancer or DCIS at the surgical resection margins\n    * No gross residual adenopathy\n    * Planning to undergo radiation therapy to the breast with or without regional lymphatics after completion of chemotherapy\n* No active hepatic or biliary disease\n\n  * Patients with liver metastases, stable chronic liver disease, Gilbert's syndrome, or asymptomatic gallstones are eligible\n* Hormone receptor status:\n\n  * Estrogen receptor and progesterone receptor status known\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Absolute neutrophil count \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Hemoglobin \u2265 10.0 g/dL\n* Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* AST and ALT \u2264 2.5 times ULN\n* Alkaline phosphatase \u2264 2.5 times ULN\n* Creatinine normal OR creatinine clearance \u2265 60 mL/min\n* LVEF \u2265 50% by MUGA scan or echocardiogram\n* Able to complete questionnaire(s) by themselves or with assistance\n* Able and willing to provide blood and tissue samples\n* No known sensitivity to benzyl alcohol\n* No sensory neuropathy \u2265 grade 2\n* No active cardiac disease, including any of the following:\n\n  * Myocardial infarction within the past 6 months\n  * Prior or concurrent congestive heart failure\n  * Prior or concurrent arrhythmia or cardiac valvular disease requiring medications or that is clinically significant\n  * Uncontrolled hypertension, defined as diastolic blood pressure (BP) \\>100 mm Hg or systolic BP \\> 200 mm Hg on 2 separate occasions \u2265 14 days apart\n  * Clinically significant pericardial effusion\n  * Prior or concurrent uncontrolled or symptomatic angina\n  * Other cardiac condition that, in the opinion of the treating physician, would put the patient at hazardous risk\n* No history of allergic reactions attributed to compounds of similar chemical or biologic composition as lapatinib ditosylate\n* No uncontrolled intercurrent illness including, but not limited to, the following:\n\n  * Ongoing or active infection\n  * Psychiatric illness or social situations that would preclude study compliance\n* Able to swallow and retain oral medication\n\n  * No history of gastrointestinal (GI) disease resulting in an inability to take oral medication, including any of the following:\n\n    * Malabsorption syndrome\n    * Requirement for IV alimentation\n    * Prior surgical procedures affecting absorption\n    * Uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 6 months after completion of study treatment\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer\n* No primary breast radiation therapy as part of breast-conserving treatment\n* No prior anthracycline or taxane therapy for any malignancy\n* No prior epidermal growth factor receptor-targeting therapies (e.g., gefitinib, cetuximab, erlotinib hydrochloride, rituximab, trastuzumab \\[Herceptin\u00ae\\], lapatinib ditosylate, panitumumab, or nimotuzumab)\n* At least 14 days since prior and no concurrent CYP3A4 inducers, including the following:\n\n  * Rifamycin-class antibiotics (e.g., rifampin, rifabutin, or rifapentine)\n  * Anticonvulsants (e.g., phenytoin, carbamazepine, or barbiturates \\[e.g., phenobarbital\\])\n  * Antiretrovirals (e.g., efavirenz or nevirapine)\n  * Glucocorticoids (e.g., oral cortisone, hydrocortisone, prednisone, methylprednisolone, or dexamethasone)\n\n    * Daily oral dexamethasone \u2264 1.5 mg (or equivalent) allowed\n  * Modafinil\n  * Hypericum perforatum (St. John's wort)\n* At least 7 days since prior and no concurrent CYP3A4 inhibitors, including the following:\n\n  * Antibiotics (e.g., clarithromycin, erythromycin, or troleandomycin)\n  * Antifungals (e.g., itraconazole, ketoconazole, fluconazole \\[\\> 150 mg daily\\], or voriconazole)\n  * Antiretrovirals and protease inhibitors (e.g., delaviridine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, or lopinavir)\n  * Calcium channel blockers (e.g., verapamil or diltiazem)\n  * Antidepressants (e.g., nefazodone or fluvoxamine)\n  * Gastrointestinal agents (e.g., cimetidine or aprepitant)\n  * Grapefruit and grapefruit juice\n* At least 6 months since prior and no concurrent amiodarone\n* No herbal or alternative medicines or supplements \u2265 14 days before, during, and for 30 days after completion of study treatment\n* No concurrent hormonal agents (e.g., birth control pills, ovarian hormonal replacement therapy, or raloxifene)\n\n  * Adjuvant hormonal agents (e.g., tamoxifen, aromatase inhibitors) allowed after completion of chemotherapy as part of treatment for breast cancer\n* No concurrent antiretroviral therapy for HIV-positive patients\n* No concurrent digitalis or beta-blockers for congestive heart failure\n* No concurrent arrhythmia or angina pectoris medication\n* No other concurrent investigational agents or anticancer therapies, including cytotoxic agents or immunotherapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}